Drug Insight: Primary medical therapy of acromegaly

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 2, 2006, Pages 109-117

  Katznelson, Laurence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Growth hormone; Primary medical therapy; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; ADJUVANT THERAPY; BRAIN RADIATION; DRUG EFFICACY; DRUG SAFETY; GAMMA KNIFE RADIOSURGERY; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT INDICATION; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM;

ACROMEGALY; CLINICAL TRIALS; DOPAMINE AGONISTS; HUMAN GROWTH HORMONE; HUMANS; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 33748652910     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0096     Document Type: Review

References (61)

1. Alexander L et al. (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12: 71-79
2. Colao A et al. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152
3. Katznelson L (2005) Diagnosis and treatment of acromegaly. Growth Horm IGF Res 15 (Suppl 1): S31-S35
4. Melmed S (1990) Acromegaly. N Engl J Med 322: 966-977
5. Molitch ME (1992) Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 21: 597-614
6. Colao A et al. (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85: 3132-3140
7. Colao A et al. (2004) The heart: an end-organ of GH action. Eur J Endocrinol 151 (Suppl 1): S93-S101
8. Grunstein RR et al. (1991) Sleep apnea in acromegaly. Ann Intern Med 115: 527-532
9. Colao A et al. (2003) Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 58: 169-176
10. Grunstein RR et al. (1994) Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121: 478-483
11. Jenkins PJ (2004) Acromegaly and cancer. Horm Res 62 (Suppl 1): 108-115
12. Pollak MN et al. (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518
13. Ron E et al. (1991) Acromegaly and gastrointestinal cancer. Cancer 68: 1673-1677
14. Delhougne B et al. (1995) The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 80: 3223-3226
15. Bengtsson BA et al. (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223: 327-335
16. Abosch A et al. (1998) Trans-sphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83: 3411-3418
17. Swearingen B et al. (1998) Long-term mortality after trans-sphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83: 3419-3426
18. Holdaway IM et al. (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89: 667-674
19. Barker FG Jr et al. (2003) Trans-sphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88: 4709-4719
20. Fahlbusch R et al. (1992) Surgical management of acromegaly. Endocrinol Metab Clin North Am 21: 669-692
21. Nomikos P et al. (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152: 379-387
22. Sheaves R et al. (1996) Outcome of trans-sphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45: 407-413
23. Biermasz NR et al. (2000) Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85: 2476-2482
24. Powell JS et al. (2000) Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 85: 2068-2071
25. Barkan AL et al. (1997) Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82: 3187-3191
26. Landolt AM et al. (1998) Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 88: 1002-1008
27. Castinetti F et al. (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90: 4483-4488
28. Freda PU et al. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90: 4465-4473
29. Colao A et al. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81: 2356-2362
30. Bevan JS et al. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87: 4554-4563
31. Saveanu A et al. (2002) Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87: 5545-5552
32. Colao A et al. (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82: 518-523
33. Abs R et al. (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83: 374-378
34. Trainer PJ et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177
35. van der Lely AJ et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358: 1754-1759
36. Herman-Bonert VS et al. (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85: 2958-2961
37. van der Lely AJ et al. (2001) Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86: 478-481
38. Barkan AL et al. (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90: 5684-5691
39. Holdaway IM (2004) Treatment of acromegaly. Horm Res 62 (Suppl 3): 79-92
40. Feenstra J et al. (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365: 1644-1646
41. Ayuk J et al. (2004) Efficacy of sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 60: 375-381
42. Newman CB et al. (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83: 3034-3040
43. Lucas T et al. (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58: 471-481
44. Amato G et al. (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56: 65-71
45. Melmed S et al. (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90: 4405-4410
46. Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90: 1856-1863
47. Resmini E et al. (2005) Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. J Endocrinol Invest 28: 166-169
48. Abe T and Ludecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145: 137-145
49. Colao A et al. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86: 2779-2786
50. Lundin P et al. (1997) Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am J Neuroradiol 18: 765-772
51. Danila DC et al. (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86: 2976-2981
52. Rickels MR and Snyder PJ (2004) Cabergoline decreases somatotroph adenoma size: a case report. Pituitary 7: 107-110
53. Petrossians P et al. (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152: 61-66
54. Colao A et al. (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82: 3308-3314
55. Yin J et al. (2005) Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and trans-sphenoidal surgery. Chin Med Sci J 20: 23-26
56. Tamura M et al. (1998) Preoperative treatment of growth hormone-producing pituitary adenoma with continuous subcutaneous infusion of octreotide. Endocr J 45: 269-275
57. Barkan AL et al. (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67: 1040-1048
58. Tachibana E et al. (1999) Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas. Neurol Med Chir (Tokyo) 39: 496-499
59. Stevenaert A and Beckers A (1996) Presurgical octreotide: treatment in acromegaly. Metabolism 45 (Suppl 1): 72-74
60. Biermasz NR et al. (1999) Direct postoperative and follow-up results of trans-sphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84: 3551-3555
61. Kristof RA et al. (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141: 399-405